{"id":"W3164197656","doi":"10.1016/s1470-2045(21)00152-2","title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":648,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; British Microcirculation Society; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Bayer; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; LEO Pharma Research Foundation; Pfizer","keywords":"Medicine; Pembrolizumab; Carboplatin; Gemcitabine; Chemotherapy; Oncology; Internal medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Population; Cisplatin; Cancer; Immunotherapy; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002480952,0.002509977,0.004162031,0.000577786,0.0005655047,0.001565471,0.001362697,0.002699024,0.01179272],"category_scores_gemma":[0.002217419,0.0009400446,0.003582639,0.0005782025,0.001543637,0.001971037,0.0006453112,0.005456705,0.002023682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001321682,"about_ca_system_score_gemma":0.001377877,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001710895,"about_ca_topic_score_gemma":0.003389969,"domain_scores_codex":[0.9991696,0.0004382414,0.00003726608,0.0001666247,0.00004534709,0.0001429295],"domain_scores_gemma":[0.9989877,0.0003302756,0.0001949141,0.00007412837,0.00004719711,0.0003657432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830621,0.003347754,0.0001452182,0.0006942588,0.0007557115,0.00001986991,0.00004086585,0.000329758,0.001189562,0.000106112,0.0008385159,0.009470177],"study_design_scores_gemma":[0.9650152,0.03326721,0.0004735512,0.00003401847,0.0003222016,0.0000192797,0.0000144374,0.0002130665,0.0001288153,0.0001431394,0.0003573554,0.00001167531],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9686078,0.01198554,0.001341552,0.002158534,0.001775878,0.006199923,0.003327472,0.0003096708,0.004293576],"genre_scores_gemma":[0.9719152,0.006288302,0.002670156,0.002274441,0.0006695912,0.005835942,0.002353842,0.00006896683,0.007923599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01179272,"threshold_uncertainty_score":0.03945059,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1011570383933493,"score_gpt":0.4104142656501243,"score_spread":0.309257227256775,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}